Novo Nordisk's CagriSema Selloff is Overdone, UBS Says -- Market Talk

Dow Jones

Jan 08, 2025

1355 GMT - The recent share selloff following disappointing trial results of Novo Nordisk's experimental anti-obesity treatment is overdone, UBS analyst Jo Walton writes. "The CagriSema phase 3 data in obesity was undoubtedly disappointing but it is still a higher efficacy treatment that could still show differentiation in type-2 diabetes." UBS says Novo remains the most exciting growth story in European pharmaceuticals and is well placed to continue to benefit from the high demand for GLP-1 medications near-term. UBS upgrades Novo Nordisk to buy from neutral and lowers its price target to 750 Danish kroner from 1,100 kroner. Shares rise 3.1% higher to 621.50 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

January 08, 2025 08:55 ET (13:55 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2501727219"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501727219\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501727219?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501727219","market":"nz","top_or_hot":-1,"title":"Novo Nordisk's CagriSema Selloff is Overdone, UBS Says -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1355 GMT - The recent share selloff following disappointing trial results of Novo Nordisk's experimental anti-obesity treatment is overdone, UBS analyst Jo Walton writes. \"The CagriSema phase 3 data in obesity was undoubtedly disappointing but it is still a higher efficacy treatment that could still show differentiation in type-2 diabetes.\" UBS says Novo remains the most exciting growth story in European pharmaceuticals and is well placed to continue to benefit from the high demand for GLP-1 medications near-term. UBS upgrades Novo Nordisk to buy from neutral and lowers its price target to 750 Danish kroner from 1,100 kroner. Shares rise 3.1% higher to 621.50 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 08:55 ET (13:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's CagriSema Selloff is Overdone, UBS Says -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's CagriSema Selloff is Overdone, UBS Says -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-08 21:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1355 GMT - The recent share selloff following disappointing trial results of Novo Nordisk's experimental anti-obesity treatment is overdone, UBS analyst Jo Walton writes. \"The CagriSema phase 3 data in obesity was undoubtedly disappointing but it is still a higher efficacy treatment that could still show differentiation in type-2 diabetes.\" UBS says Novo remains the most exciting growth story in European pharmaceuticals and is well placed to continue to benefit from the high demand for GLP-1 medications near-term. UBS upgrades Novo Nordisk to buy from neutral and lowers its price target to 750 Danish kroner from 1,100 kroner. Shares rise 3.1% higher to 621.50 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 08:55 ET (13:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2501727219","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501727219","pubTimestamp":1736344500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1355 GMT - The recent share selloff following disappointing trial results of Novo Nordisk's experimental anti-obesity treatment is overdone, UBS analyst Jo Walton writes. \"The CagriSema phase 3 data in obesity was undoubtedly disappointing but it is still a higher efficacy treatment that could still show differentiation in type-2 diabetes.\" UBS says Novo remains the most exciting growth story in European pharmaceuticals and is well placed to continue to benefit from the high demand for GLP-1 medications near-term. UBS upgrades Novo Nordisk to buy from neutral and lowers its price target to 750 Danish kroner from 1,100 kroner. Shares rise 3.1% higher to 621.50 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"瑞银称诺和诺德的CagriSema抛售过度——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"1355 GMT - The recent share selloff following disappointing trial results of Novo Nordisk's experimental anti-obesity treatment is overdone, UBS analyst Jo Walton writes. \"The CagriSema phase 3 data in obesity was undoubtedly disappointing but it is still a higher efficacy treatment that could still show differentiation in type-2 diabetes.\" UBS says Novo remains the most exciting growth story in European pharmaceuticals and is well placed to continue to benefit from the high demand for GLP-1 medications near-term. UBS upgrades Novo Nordisk to buy from neutral and lowers its price target to 750 Danish kroner from 1,100 kroner. Shares rise 3.1% higher to 621.50 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 08:55 ET (13:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}